Back to News
Market Impact: 0.2
Immutep Receives A$2.16 Mln French Tax Incentive To Support Drug Development
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Immutep received a €1.36 million cash payment, approximately A$2.16 million, under the French government's research tax incentive program. The payment provides funding to the clinical-stage immunotherapy company; no broader financial or market impact was reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
IMMP0.30
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target